NASDAQ:OKUR OnKure Therapeutics (OKUR) Stock Price, News & Analysis $2.94 -0.16 (-5.16%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$2.95 +0.01 (+0.34%) As of 05:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About OnKure Therapeutics Stock (NASDAQ:OKUR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get OnKure Therapeutics alerts:Sign Up Key Stats Today's Range$2.90▼$3.2450-Day Range$2.88▼$4.3252-Week Range$2.23▼$5.38Volume149,746 shsAverage Volume153,937 shsMarket Capitalization$118.76 millionP/E RatioN/ADividend YieldN/APrice Target$17.50Consensus RatingHold Company Overview OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company is working to discover and advance small-molecule therapies designed to target biological pathways involved in tumor growth and the suppression of antitumor immune responses. Its lead investigational product candidate, OKN4395, is an orally administered small-molecule antagonist of the EP4 receptor, which is associated with tumor-promoting inflammation and immune suppression. OnKure is evaluating OKN4395 as a potential treatment for advanced solid tumors, including in combination with immune checkpoint inhibitors. The company’s programs are being developed for patients with cancers that may benefit from targeted approaches to the tumor microenvironment. OnKure Therapeutics is headquartered in Boulder, Colorado, and its development activities are focused on advancing oncology candidates through clinical testing and potential regulatory approval. As with other clinical-stage biotechnology companies, its product candidates remain investigational and are subject to the results of clinical trials and regulatory review.AI Generated. May Contain Errors. Read More OnKure Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreOKUR MarketRank™: OnKure Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 546th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingHold Consensus RatingOnKure Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialOnKure Therapeutics has a consensus price target of $17.50, representing about 495.2% upside from its current price of $2.94.Amount of Analyst CoverageOnKure Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about OnKure Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OnKure Therapeutics are expected to grow in the coming year, from ($1.71) to ($1.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OnKure Therapeutics is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OnKure Therapeutics is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOnKure Therapeutics has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about OnKure Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.35% of the float of OnKure Therapeutics has been sold short.Short Interest Ratio / Days to CoverOnKure Therapeutics has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in OnKure Therapeutics has recently increased by 23.34%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOnKure Therapeutics does not currently pay a dividend.Dividend GrowthOnKure Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment-1.00 News SentimentOnKure Therapeutics has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for OnKure Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for OKUR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, OnKure Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,155.00 in company stock.Percentage Held by Insiders2.17% of the stock of OnKure Therapeutics is held by insiders.Percentage Held by Institutions90.98% of the stock of OnKure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OnKure Therapeutics' insider trading history. Receive OKUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OnKure Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OKUR Stock News HeadlinesOnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare ConferenceAugust 31, 2026 | globenewswire.comOnKure Therapeutics Inc. - Ordinary Shares - Class AAugust 19, 2026 | money.usnews.comWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the dot-com era split Pets.com from Amazon. One robotics business tied to his research posted $100 million in quarterly revenue, a fifth straight quarter of sequential growth, and 33.4% year-over-year growth. Meanwhile, three hyped names on his avoid list still depend on story over substance. See the full breakdown in his Great AI Shock briefing.September 24 at 1:00 AM | The Oxford Club (Ad)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), OnKure Therapeutics (OKUR) and Alnylam Pharma (ALNY)August 6, 2026 | theglobeandmail.comOnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business HighlightsAugust 4, 2026 | globenewswire.comOnKure Therapeutics Stock Short Interest Report | NASDAQ:OKUR | BenzingaJuly 14, 2026 | benzinga.comOnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026July 2, 2026 | globenewswire.comOnKure Therapeutics, Inc. Class AJune 9, 2026 | edition.cnn.comSee More Headlines OKUR Stock Analysis - Frequently Asked Questions How have OKUR shares performed this year? OnKure Therapeutics' stock was trading at $2.90 at the beginning of the year. Since then, OKUR shares have increased by 1.4% and is now trading at $2.94. How were OnKure Therapeutics' earnings last quarter? OnKure Therapeutics, Inc. (NASDAQ:OKUR) issued its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.31) earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.23. Who are OnKure Therapeutics' major shareholders? Top institutional investors of OnKure Therapeutics include Seven Fleet Capital Management LP (0.60%) and Bank of New York Mellon Corp (0.18%). Insiders that own company stock include Jason A Leverone and Nicholas A Saccomano. View institutional ownership trends. How do I buy shares of OnKure Therapeutics? Shares of OKUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/04/2026Today9/24/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 2 weeks, OKUR's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:OKUR Previous SymbolNASDAQ:OKUR CIK1637715 Webwww.onkuretherapeutics.com Phone(720) 307-2892FaxN/AEmployees45Year FoundedN/APrice Target and Rating Average Price Target for OnKure Therapeutics$17.50 High Price Target$21.00 Low Price Target$14.00 Potential Upside/Downside+495.2%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($3.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59.52 million Net MarginsN/A Pretax MarginN/A Return on Equity-49.01% Return on Assets-45.77% Debt Debt-to-Equity RatioN/A Current Ratio26.75 Quick Ratio26.75 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.11 per share Price / Book0.72Miscellaneous Outstanding Shares40,395,000Free Float39,518,000Market Cap$118.76 million OptionableN/A Beta0.23 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:OKUR) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredCongress Passes Landmark Digital Asset Law Wall Street Is WatchingThe House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...Awesomely | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OnKure Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OnKure Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
